Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemvaleukin alfa + Pembrolizumab in Platinum-Resistant Ovarian Cancer
NCT05092360Phase 3Terminated
- Sponsor
- Mural Oncology
- Start
- Jan 2022
- Primary completion
- Jan 2025
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 14
01
Overview
A Phase 3 trial of nemvaleukin alfa in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Mural Oncology. Started Jan 2022; status: terminated.
02
Drugs
nemvaleukin alfa
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05092360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05092360.